- Home
- BYSI
BYSI
BeyondSpring Inc.
as of 12-02-2025 4:00pm EST
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | FLORHAM PARK |
| Market Cap: | 79.0M | IPO Year: | 2017 |
| Target Price: | N/A | AVG Volume (30 days): | 23.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.98 - $3.44 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered BYSI Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of BeyondSpring Inc. (BYSI)
Avg Cost/Share
$1.76
Shares
45,513
Total Value
$80,102.88
Owned After
1,518,893
SEC Form 4
Avg Cost/Share
$1.72
Shares
85,798
Total Value
$147,572.56
Owned After
1,518,893
SEC Form 4
Avg Cost/Share
$1.65
Shares
17,960
Total Value
$29,634.00
Owned After
1,518,893
SEC Form 4
Avg Cost/Share
$1.65
Shares
28,495
Total Value
$47,016.75
Owned After
1,518,893
SEC Form 4
Avg Cost/Share
$1.70
Shares
107,361
Total Value
$182,513.70
Owned After
1,518,893
SEC Form 4
Avg Cost/Share
$1.77
Shares
2,390
Total Value
$4,230.30
Owned After
1,518,893
SEC Form 4
Avg Cost/Share
$1.81
Shares
3,979
Total Value
$7,201.99
Owned After
1,518,893
SEC Form 4
Avg Cost/Share
$1.77
Shares
7,507
Total Value
$13,287.39
Owned After
1,518,893
SEC Form 4
Avg Cost/Share
$1.79
Shares
2,100
Total Value
$3,759.00
Owned After
1,518,893
SEC Form 4
Avg Cost/Share
$1.78
Shares
17,500
Total Value
$31,150.00
Owned After
1,518,893
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Oct 17, 2025 | Sell | $1.76 | 45,513 | $80,102.88 | 1,518,893 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Oct 16, 2025 | Sell | $1.72 | 85,798 | $147,572.56 | 1,518,893 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Oct 15, 2025 | Sell | $1.65 | 17,960 | $29,634.00 | 1,518,893 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Oct 14, 2025 | Sell | $1.65 | 28,495 | $47,016.75 | 1,518,893 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Oct 13, 2025 | Sell | $1.70 | 107,361 | $182,513.70 | 1,518,893 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Oct 10, 2025 | Sell | $1.77 | 2,390 | $4,230.30 | 1,518,893 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Oct 9, 2025 | Sell | $1.81 | 3,979 | $7,201.99 | 1,518,893 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Oct 8, 2025 | Sell | $1.77 | 7,507 | $13,287.39 | 1,518,893 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Oct 7, 2025 | Sell | $1.79 | 2,100 | $3,759.00 | 1,518,893 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Oct 6, 2025 | Sell | $1.78 | 17,500 | $31,150.00 | 1,518,893 |
Compare BYSI vs Leading Stocks
See how BYSI stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BYSI BeyondSpring Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.